Leerink Partnrs Has Bullish Estimate for Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR) – Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Cencora in a report issued on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $4.23 per share for the quarter, up from their prior estimate of $4.12. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

Several other research firms have also recently issued reports on COR. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company lowered their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Stock Down 0.2 %

COR opened at $228.69 on Monday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. Cencora has a 12 month low of $208.58 and a 12 month high of $253.27. The stock has a market capitalization of $44.20 billion, a P/E ratio of 30.45, a P/E/G ratio of 1.54 and a beta of 0.49. The business has a 50 day simple moving average of $237.34 and a 200-day simple moving average of $233.53.

Institutional Trading of Cencora

A number of institutional investors and hedge funds have recently made changes to their positions in COR. Concord Wealth Partners purchased a new stake in Cencora during the third quarter valued at about $30,000. SYSTM Wealth Solutions LLC purchased a new stake in shares of Cencora during the 2nd quarter worth about $36,000. Ashton Thomas Securities LLC purchased a new position in Cencora in the third quarter valued at approximately $41,000. Fairscale Capital LLC acquired a new stake in shares of Cencora in the second quarter worth $54,000. Finally, Modus Advisors LLC purchased a new position in shares of Cencora in the 4th quarter valued at $54,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock valued at $22,862,734 over the last quarter. Insiders own 15.80% of the company’s stock.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.